MAP3K5 and metabolic dysfunction-associated steatohepatitis: Novel ASK1 inhibitors are being developed and have shown promise in Phase 2 clinical trials for Nonalcoholic Steatohepatitis (NASH), Pulmonary Arterial Hypertension (PAH) and Diabetic Kidney Disease (DKD) (44).